882672-05-1

Basic information

• Product Name: 6-Bromo-2-chloroquinazoline
• Synonyms: 6-bromo-2-chloroquinazoline;6-BroMo-2-chloroquinazoli...;6-Bromo-2-chloroquizoline
• CAS NO: 882672-05-1
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.49
• Product Categories: CHIRAL CHEMICALS
• Mol File: 882672-05-1.mol

Chemical Properties

• Boiling Point: 240.2 °C at 760 mmHg
• Flash Point: 99.1 °C
• Appearance: /
• Density: 1.762
• Vapor Pressure: 0.0596mmHg at 25°C
• Refractive Index: 1.691
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.54±0.30(Predicted)
• CAS DataBase Reference: 6-Bromo-2-chloroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2-chloroquinazoline(882672-05-1)
• EPA Substance Registry System: 6-Bromo-2-chloroquinazoline(882672-05-1)

Safety Data

• Hazardous Substances Data: 882672-05-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-2-chloroquinazoline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into complex molecular structures, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Bromo-2-chloroquinazoline is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its reactivity and potential to form bioactive molecules that can control or eliminate pests and weeds.
Used in Materials Science:
6-Bromo-2-chloroquinazoline is employed in materials science for the development of novel materials with specific properties, such as optoelectronic materials, where its aromatic and halogenated nature can influence the material's electronic and optical characteristics.
Used as a Research Reagent:
6-Bromo-2-chloroquinazoline serves as a valuable research reagent in laboratories, where it is used to study chemical reactions and develop new compounds. Its unique structure allows researchers to explore its reactivity and potential applications in various chemical processes.

InChI:InChI=1/C8H4BrClN2/c9-6-1-2-7-5(3-6)4-11-8(10)12-7/h1-4H

Upstream product

• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 20712-12-3 (2-amino-5-bromophenyl)methanol 
• 29124-57-0 2-amino-5-bromobenzaldehyde 
• 79885-37-3 6-bromoquinazolin-2-ol 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 190273-89-3 6-bromoquinazolin-2-ylamine 

Downstream Products

• 1008505-74-5 6-bromo-N-(4-morpholin-4-ylphenyl)quinazolin-2-amine 
• 1008506-08-8 6-bromo-N-[4-(2-methoxyethoxy)phenyl]quinazolin-2-amine 
• 1008505-87-0 N-{4-[(6-bromoquinazolin-2-yl)amino]phenyl}-N-methylacetamide 
• 1008505-75-6 N-{4-[(6-bromoquinazolin-2-yl)amino]phenyl}acetamide 
• 1008506-12-4 N′-(6-bromoquinazolin-2-yl)-N-(2-methoxyethyl)-N-methylbenzene-1,4-diamine 
• 1538605-06-9 2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazoline 
• 1538605-09-2 6-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(2-methyl-6-nitrophenyl)quinazolin-2-amine 
• 1538604-68-0 BLU9931 
• 1538605-05-8 2-chloro-6-(3,5-dimethoxyphenyl)quinazoline 
• 882670-77-1 (6-bromo-quinazolin-2-yl)-methylamine 
• 882671-99-0 (6-bromo-quinazolin-2-yl)-phenyl-amine 
• 1008506-03-3 6-bromo-N-(4-fluorophenyl)quinazolin-2-amine 
• 1036745-17-1 C₁₆H₁₃BrN₄O 

Relevant articles and documents

Inhibitors of the fibroblast growth factor receptor

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

Deuterium kinase selective inhibitor

The invention relates to a deuterium kinase selective inhibitor and provides a compound shown as formula (I), a stereoisomer, a tautomer or pharmaceutically acceptable salt thereof and the application of the compound used as FGFR4 kinase selective inhibit

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.